Agios Pharmaceuticals, Inc. (AGIO) CEO Jacqualyn Fouse on Q2 2020 Results - Earnings Call Transcript

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q2 2020 Results Earnings Conference Call July 30, 2020 8:00 AM ET

Company Participants

Holly Manning - Director of Investor Relations
Jacqualyn Fouse - Chief Executive Officer
Chris Bowden - Chief Medical Officer
Darrin Miles - SVP, U.S. Commercial & Global Marketing
Andrew Hirsch - Chief Financial Officer and Head of Corporate Development
Bruce Car - Chief Scientific Officer

Conference Call Participants

Alethia Young - Cantor
Anupam Rama - JPMorgan
Tyler Van Buren - Piper Sandler
Peter Lawson - Barclays
Kennen MacKay - RBC Capital Markets
Chris Shibutani - Cowen
Michael Schmidt - Guggenheim
Mark Breidenbach - Oppenheimer

Operator

Good morning, and welcome to Agios' Second Quarter 2020 Conference Call. At this time, all participants are in a listen-only mode. There will be a question-and-answer session at the end. Please be advised that this call is being recorded at Agios' request.

I would now like to turn the call over to Holly Manning, Director of Investor Relations.

Holly Manning

Thank you, operator. Good morning, everyone, and welcome to Agios' second quarter 2020 conference call. You can access slides for today's call by going to the Investors section of our website, agios.com. With me on the call today with prepared remarks are Dr. Jackie Fouse, our Chief Executive Officer; Dr. Chris Bowden, our Chief Medical Officer; Darrin Miles, our Senior Vice President of U.S. Commercial and Global Marketing; and Andrew Hirsch, our Chief Financial Officer and Head of Corporate Development. Dr. Bruce Car, our Chief Scientific Officer will join for Q&A.

Before we get started, I would like to remind everyone that some of the statements we make on this call will include forward-looking statements. Actual events and results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties and other